Urolithiasis patients with hyperuricemia
Conditions
Interventions
Feburic tablets
Uralyt
Feburic tablets and Uralyt
No medication
Sponsors
Kanazawa Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) More than 20 years old Japanese male patient age at the time of obtaining informed consent. 2) Patients with serum uric acid level are greater than 7.0mg/dl. 3) Patient in the previous two weeks, not taking uric acid-lowering drugs. 4) Informed consent.
Exclusion criteria
Exclusion criteria: 1) The patient who is developing gouty arthritis at the time of an eligibility judging, or has not passed two weeks since a gout arthritis disappearance day. 2) The patient who has not passed two weeks since the last medication day of the following combined use prohibition medicine at the time of an eligibility judging. Combined use prohibition drug of "Febric tablets". Mercaptopurine hydrate Azathioprine Combined use prohibition drug of "Uralyt". Hexamine mandelate 3) Serum creatinine level is more than 1.5 mg/dl. 4) Liver disease patients (either AST or ALT exceeds the twice of a standard value maximum). 5) Patients with severe cardiac disease, renal failure and other critical diseases. 6) Patients with drug allergy. 7) Patients who are considered to be inappropriate by the investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the clinical laboratory test result in four weeks of study, and the degree of super saturation of a calcium oxalate or calcium phosphate. | — |
Countries
Japan
Contacts
Public ContactKatsuhito Miyazawa
Kanazawa Medical University Urology
Outcome results
None listed